Introduction
============

Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder which manifests as isolated glucocorticoid deficiency with normal mineralocorticoid function [@bib1]. This potentially lethal condition is caused by adrenal resistance to ACTH and is clinically characterised by low serum cortisol concentrations in the presence of markedly elevated plasma ACTH levels. FGD patients typically present with hyperpigmentation, hypoglycaemic seizures and failure to thrive in the neonatal period or late childhood [@bib1]. However, some milder genotypes have been presented in later years [@bib3].

FGD is a genetically heterogeneous entity. Inactivating mutations in the ACTH receptor also known as the melanocortin 2 receptor (MC2R) were first identified as the cause of FGD in 1993 [@bib5]. This is now termed FGD type 1 (OMIM\#202200) and accounts for up to 25% of cases. In 2005, Metherell *et al*. [@bib7] showed that mutations in the MC2R accessory protein (MRAP), which is essential for trafficking of MC2R from the endoplasmic reticulum (ER) to the cell surface and subsequent signalling in response to ACTH, are responsible for a further ∼20% of FGD cases, now named FGD type 2 (OMIM \#607398). To date, over 25 loss-of-function mutations in MC2R and 11 in MRAP have been reported [@bib1]. These MRAP mutations are summarised in [Table 1](#tbl1){ref-type="table"}. Recently, certain 'less severe' mutations in STAR protein (STAR) (R192C and R188C) have been reported to be responsible for a phenotype identical to FGD types 1 and 2 and classified as FGD type 3 [@bib3]. Over the last few years we have identified cases of FGD that vary from the classical phenotype. These include cases of late onset FGD [@bib3], cases describing mild disturbances in angiotensin--renin--aldosterone axis in severe FGD [@bib9] and genetic overlap with conditions associated with mineralocorticoid insufficiency [@bib3]. This adds to the complexity of making a diagnosis and highlights the importance of genetic testing.

We report an Indian child with severe generalised hyperpigmentation at birth who presented with recurrent hypoglycaemic seizures from 36 h of life due to a novel homozygous splice mutation (c.106+2_3dupTA) in *MRAP*. Using an *in vitro* splicing assay, we demonstrate that the mutation leads to disrupted mRNA splicing and exon 3 skipping.

Case history
============

The index case presented at birth with intense generalised hyperpigmentation ([Fig. 1](#fig1){ref-type="fig"}A). The male infant was born at term, birth weight 2.8 kg to non-consanguineous Indian parents with a fair complexion. He had normal male genitalia. There was a family history of three previous miscarriages for which no cause was identified. At 36 h of life, he developed high fever, lethargy and poor feeding. He was hypoglycaemic with blood glucose of 20 mg/dl. Treatment with i.v. glucose was initiated but despite this he suffered four further episodes of hypoglycaemia, twice accompanied by seizures. Serum electrolytes were normal. Endocrine investigations revealed low serum cortisol 0.22 μg/dl (NR 1.7--14) with a flat response post administration of a standard synacthen test 0.018 μg/dl. Normal plasma renin activity of 5.72 ng/ml per h (NR 2.0--35.0) and plasma aldosterone of 97.9 ng/l (NR supine 10--160) confirmed the diagnosis of isolated cortisol deficiency in this case. 17-OHP levels were normal (2 ng/ml) and did not rise after a standard synacthen test (1.5 ng/ml). Plasma ACTH was measured after 3 days of hydrocortisone therapy and was 170 pg/ml (NR 10--50). The adrenal glands were not visualised on abdominal ultrasound or computed tomography of the abdomen but seen on magnetic resonance imaging and reported as bilaterally small, highlighting the difficulty of adrenal imaging in young children.

Whilst on an initial oral replacement hydrocortisone dose of 20 mg/m^2^ per day, his skin significantly lightened. Over the next 3 years he had four further episodes of hypoglycaemic seizures precipitated by viral illness. Plasma ACTH at the age of 14 months was \>2000 pg/ml, related to poor treatment compliance. This improved and his dose of hydrocortisone was reduced to 15 mg/m^2^ per day. Subsequent ACTH concentrations at the age of 2 and 3.5 years were 5.7 and 25.2 pg/ml respectively.

Despite abnormal neurological tests during the neonatal period, with extinguished response on visual evoked responses and a flat curve on brainstem evoked response to audiometry, he achieved all milestones at an appropriate age with normal hearing and vision at 3.5 years of age. Aged 3.5 years his height was 87 cm (−3.5 SDS) and weight 12.5 kg (−2 SDS). However, the height velocity over the past year is greater than −1 SDS and the short stature may be a reflection of the short mid-parental height of 160 cm (−2.5 SDS).

In view of the diagnosis of isolated glucocorticoid insufficiency, blood was obtained from the infant and both parents and molecular genetic analysis was performed.

Materials and methods
=====================

Sequencing
----------

Genomic DNA was extracted from blood leucocytes. Informed patient consent was obtained. PCR and sequencing of the coding exons of *MC2R* and *MRAP* was performed using patient or parental genomic DNA. Primers were designed to intronic sequences (sequences available on request). PCR products were sequenced in both directions using ABI Prism Big Dye Sequencing kit on an ABI 377 automated DNA sequencer (Applied Biosystems). The mutation was described according to recommended nomenclature [@bib11].

*In vitro* splicing assay
-------------------------

To demonstrate that this mutation affected mRNA splicing, MRAP exon 3 and its wild type (MRAP wt) or mutated (MRAP mt) flanking intronic sequences were introduced into a well-characterised splicing reporter derived from the adenovirus major late (AdML-Par) first and second leader exons. *In vitro* splicing experiments were performed as described previously [@bib12].

Results
=======

*MC2R* was found to be normal on sequencing. A novel homozygous two base pair duplication mutation at the splice junction of exon 3/intron 3 (c.106+2_3dupTA) was detected in *MRAP* in the affected child ([Fig. 2](#fig2){ref-type="fig"}A). Both parents were heterozygous for this mutation.

*In silico*, c.106+2_3dupTA mutation is predicted to disrupt splicing. An *in vitro* splicing assay showed that after 1 h incubation under splicing condition, the wild-type minigene produced a band corresponding to the three exons (L1-MRAP_exon3-L2) joined together. This was confirmed by direct sequencing. The c.106+2_3dupTA mutation in the mutant minigene caused the skipping of MRAP exon 3 and resulted in a band of 186 nucleotides corresponding to exons L1 and L2 spliced together ([Fig. 2](#fig2){ref-type="fig"}B). This was confirmed by DNA sequencing. The resulting MRAP transcript would have a foreshortened open reading frame that encodes a prematurely terminated translation product. This protein (if produced) would lack the transmembrane domain that is essential for MC2R interaction.

Discussion
==========

We report a case of FGD presenting at birth due to a novel homozygous splice-site mutation of *MRAP*. *In vitro* splicing assay demonstrated that this mutation would cause skipping of exon 3 leading to a protein (if produced) lacking the transmembrane MC2R interacting domain.

The very early presentation of FGD and severe phenotype in our case is in keeping with the pathophysiology previously seen with *MRAP* splice-site and nonsense mutations [@bib1]. MRAP is a small single-pass transmembrane domain protein, which is essential for the processing of the MC2R and its trafficking from the ER to the cell surface. Mapping of the domains important for action has been undertaken by two groups [@bib13]. The transmembrane domain of MRAP encoded by exon 3 is responsible for MC2R interaction, whilst the tyrosine rich region in the N-terminus is important for MC2R trafficking; and the C-terminus regulates MC2R cell surface expression [@bib14]. In the absence of MRAP, MC2R is retained within the ER and fails to reach the cell surface [@bib7].

The majority of *MRAP* mutations reported to date are splice-site or nonsense mutations which if translated are predicted to produce proteins lacking the transmembrane domain, leading to a complete loss of receptor function and a severe phenotype [@bib1]. Such patients present with symptoms and signs of hypocortisolaemia very early on in life at a median age of 0.08 years (range: at birth to 1.6 years) [@bib2]. Recently, two homozygous missense mutations in MRAP have also been reported that are associated with a milder and variable phenotype [@bib4]. In contrast to the early presentation seen with MRAP splice-site/nonsense mutations, the index cases with missense mutations c.175T\>G (p.Y59D) and c.76T\>C (p.V26A) presented at the age of 4 and 18 years respectively. Importantly, the 18-year-old index patient presented with non-specific symptoms of fatigue, weight loss and depression. The description of these patients not only extends the phenotype of FGD but also informs us of the importance of considering this diagnosis in adults with late presentation isolated glucocorticoid deficiency.

On the other hand, more than 25 mutations reported so far in MC2R gene are missense mutations. The majority of these mutations have been shown *in vitro* to impair the trafficking of MC2R from ER to the cell surface and lead to a variable reduction in the receptor expression, which is 20--100% of the wild type [@bib2]. As highlighted by Chung *et al*. [@bib2], nonsense or frameshift mutations are associated with a severe phenotype of FGD (more common with *MRAP* mutations) whereas missense mutations give rise to a milder phenotype (more common with *MC2R* mutations).

Owing to the observation that ACTH and α-MSH are equipotent on human melanocortin 1 receptor (MC1R) [@bib18], hyperpigmentation observed in FGD has generally been thought to be due to high ACTH acting on the MC1R in melanocytes [@bib19]. Indeed other conditions that result in ACTH excess, such as Cushing\'s disease and ectopic ACTH Cushing\'s syndrome can present with hyperpigmentation although this is often less intense, reflecting the lower plasma concentrations of ACTH measured in these disorders [@bib21].

It is interesting that our patient was deeply hyperpigmented at birth. This is a feature that has been described in other case reports and would suggest that the foetal corticotrophs can produce excessive plasma ACTH in response to low foetal cortisol which in turn acts on melanocytes to promote eumelanin synthesis before birth [@bib22]. In some FGD patients the plasma ACTH levels are difficult to normalise despite large doses of hydrocortisone and they remain pigmented. In our patient normalisation of ACTH was achievable using a dose of 15 mg/m^2^ per day.

Weight and height differences have also been described. Some patients with *MC2R* mutations (FGD type 1) have been described as having tall stature [@bib2] although the molecular mechanism for this is uncertain. Our patient has short stature at the age of 3.5 years. This is probably consistent with the short stature of his parents. Early onset obesity has also been reported in one family with *MRAP* mutation [@bib16], this is not a feature noted in our patient.

In conclusion, we have presented a newborn with FGD type 2, presenting with intense hyperpigmentation and hypoglycaemic seizures. He was found to have a novel splice-site mutation in the *MRAP* gene that would cause complete loss of ACTH response, hence explaining the early presentation seen in the case. Early diagnosis and appropriate therapy enabled him to achieve normal developmental milestones despite initial abnormal tests.
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![(A) Intense generalised hyperpigmentation of index case at presentation in the neonatal period. (B) Current image of index case (consent obtained). Full colour version of this figure available via <http://dx.doi.org/10.1530/EJE-11-0581>.](EJE110581f01){#fig1}

![(A) Schematic diagram representing alternative splicing of *MRAP* exons 5 and 6. Black boxes represent coding regions and black dashed lines indicate splicing. Chromatogram showing the splice mutation (red arrow). Other known MRAP mutations are shown in blue. \*Indicates position of splice-site mutations (c.106+1G\>T, c.106+1G\>A, c.106+1G\>C, c.106+1delG and c.106+2insT). (B) *In vitro* splicing assay demonstrates that MRAP mutation c.106+2_3dupTA leads to impaired splicing and skipping of exon 3. In this assay, MRAP exon 3 flanked by either wild type (wt) or mutated (mt; c.106+2_3dupTA) MRAP intronic sequences were introduced into a splicing reporter (AdML-Par) between the first and the second leader exons, L1 and L2. The resulting minigenes, MRAP wt (L1-MRAP wt_exon3-L2), MRAP mt (L1-MRAP mt_exon3-L2) or AdML-Par (splicing reporter alone, L1--L2), were incubated in HeLa nuclear extracts for 60 min under splicing conditions at 30 °C or pre-splicing control conditions at 0 °C. Incubation temperatures, 0 or 30 °C, are indicated above each lane. The identity of the pre-mRNA and of the mRNA spliced products is schematically drawn next to the autoradiogram. The nucleotide ladder is shown on the right. Retention of MRAP exon 3 (L1-MRAP-L2) is seen with MRAP wt whilst aberrant splicing resulting in skipping of MRAP exon 3 (L1--L2) is detected in MRAP mt. Bands corresponding to correct and aberrant mRNA splice products are indicated by the arrows. Full colour version of this figure available via <http://dx.doi.org/10.1530/EJE-11-0581>.](EJE110581f02){#fig2}

###### 

Summary of published and unpublished MRAP mutations. The majority of mutations are predicted to result in absent or significantly truncated protein forms and hence complete loss of ACTH response. In comparison, c.76T\>C (p.V26A) and c.175T\>G (p.Y59D) have been shown to have impaired but not absent function. p.0? represents the recommended annotation when the effect on the protein is unknown as in the case of c.3G\>A that affect the initiation site and the splice mutations the lead to skipping of exon 3.

  **Mutation**[a](#tblfn1){ref-type="table-fn"}   **Mutation type**   **Functional effect**                                                    **Clinical presentation**   **References**
  ----------------------------------------------- ------------------- ------------------------------------------------------------------------ --------------------------- ----------------
  c.3G\>A (p.0? or p.M1?)                         MS                  Unknown (? no protein produced)                                          Classical early onset       [@bib2]
  c.17-23delACGCCTC  (p.N6MfsX24)                 NS                  Shortened protein if translated                                          Classical early onset       [@bib8]
  c.33C\>A (p.Y11X)                               NS                  Shortened protein if translated                                          Classical early onset       [@bib1]
  c.76T\>C (p.V26A)                               MS                  Full-length protein with amino acid change -- impaired cAMP generation   Late presentation           [@bib4]
  c.106+1G\>T (p.0?)                              SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       [@bib2]
  c.106+1G\>A (p.0?)                              SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       [@bib2]
  c.106+1G\>C (p.0?)                              SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       [@bib2]
  c.106+1delG (p.0?)                              SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       [@bib2]
  c.106+2insT (p.0?)                              SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       [@bib2]
  c.106+2_3dupTA (p.0?)\*                         SS                  Skipping of exon 3 (no protein or lack transmembrane domain)             Classical early onset       This study
  c.128delG (p.V44X)                              NS                  Shortened protein if translated                                          Classical early onset       [@bib7]
  c.175T\>G (p.Y59D)                              MS                  Full-length protein with amino acid change -- impaired cAMP generation   Late presentation           [@bib4]

MS, missense mutation; NS, nonsense mutation; SS, splice-site mutation; c., coding DNA; p., protein.

Mutations described according to recommended nomenclature [@bib11]. Novel mutation indicated by \*.
